Skip to main content
. 2024 Sep 15;16(9):4671–4679. doi: 10.62347/DMTS8090

Table 2.

Comparison of safety and prognosis of treatment

Groups n Recurrence No recurrence Allergy Dizziness headache Regurgitation Worsening of pain Total incidence
Control group 55 9 (47.6) 46 (23.8) 2 (3.6) 1 (1.8) 2 (3.6) 1 (1.8) 6 (10.9)
Research group 61 3 (30.4) 58 (7.1) 2 (3.3) 1 (1.6) 2 (3.3) 0 (0.0) 5 (8.2)
χ2 4.085 0.248
P 0.043 0.619